ฯใฝถสำฦต

Mei Wei
( out of 109 reviews )

Mei Wei, MD

Languages spoken: English

Clinical Locations

Huntsman Cancer Institute - Cancer Hospital North

2K, Plastic and Reconstructive Surgery
Salt Lake City

  • Dr. Wei Mei is specialized in breast medical oncology. Her research interests focus on clinical trials, breast cancer outcome research, epidemiology and patient's quality of life.

    Board Certification

    American Board of Internal Medicine
    American Board of Internal Medicine (Sub: Medical Oncology)

    Patient Rating

    4.9 /5
    ( out of 109 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    October 16, 2024
    SUGAR HOUSE HEALTH CENTER

    We are very impressed wth Dr Wei

    October 05, 2024
    HUNTSMAN CANCER CENTER

    I look forward to my follow ups with Dr. Wei. I am eternally thankful that she is my medical oncologist. She has been thorough from day one and I know she greatly cares for my well-being. Thank you for being part of my team.

    October 03, 2024
    SUGAR HOUSE HEALTH CENTER

    Dr Wei is very caring and understanding. Makes sure I understand what is happening and answers all my questions.

    October 02, 2024
    SUGAR HOUSE HEALTH CENTER

    Dr. Wei always makes me feel confident that we are doing everything in our power to treat this disease. She is very personable and takes time to answer all questions and include everyone in the decision making process. I really appreciate that she also sees patients at the Sugarhouse location which allows us to utilize their childcare facilities.

    September 26, 2024
    HUNTSMAN CANCER CENTER

    Dr Mei Wei is clear and concise in her explanations. She makes sure I understand the issues.

    September 11, 2024
    SUGAR HOUSE HEALTH CENTER

    Dr.Wei is extremely thorough and has her patients best interest at heart.A pleasure to be her patient.

    September 11, 2024
    SUGAR HOUSE HEALTH CENTER

    She was very thorough when she talked to me. She listen to my concerns. She did not change how I was feeling. I would recommend her strongly.

    September 06, 2024
    HUNTSMAN CANCER CENTER

    She cares about my well being, very friendly

    September 05, 2024
    HUNTSMAN CANCER CENTER

    Dr. Wei is good at listening and explaining and making a plan for me.

    See More Patient Comments

  • Dr. Wei Mei is specialized in breast medical oncology. Her research interests focus on clinical trials, breast cancer outcome research, epidemiology and patient's quality of life.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Oncology
    Board Certification
    American Board of Internal Medicine
    American Board of Internal Medicine (Sub: Medical Oncology)

    Education history

    Fellowship Hematology/Oncology - ฯใฝถสำฦต of Utah School of Medicine Fellow
    Residency Internal Medicine - ฯใฝถสำฦต of Utah School of Medicine Resident
    Internship Internal Medicine - ฯใฝถสำฦต of Nevada, Reno School of Medicine Intern
    Research Fellow Cancer Epidemiology - ฯใฝถสำฦต of Utah School of Medicine Postdoctoral Research Fellow
    Residency Radiation Oncology - Sun Yat-sen ฯใฝถสำฦต Cancer Center Resident
    Residency Gynecological Oncology - Sun Yat-sen ฯใฝถสำฦต Cancer Center Resident
    Professional Medical Medicine - Anhui Medical ฯใฝถสำฦต M.D.

    Selected Publications

    Journal Article

    1. Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, Allison KH, Anderson B, Bailey J, Burstein HJ, Chen N, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch AM, Lyons J, McCloskey S, McShane M, Mortimer J, Patel SA, Rosenberger LH, Rugo HS, Santa-Maria C, Schneider BP, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Wei M, Wisinski KB, Yeung KT, Young JS, Schonfeld R, Kumar R (2024). Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 22(5), 331-357. ()
    2. Vaklavas C, Matsen CB, Chu Z, Boucher KM, Scherer SD, Pathi S, Beck A, Brownson KE, Buys SS, Chittoria N, DAstous E, Gulbahce HE, Henry NL, Kimani S, Porretta J, Rosenthal R, Ward J, Wei M, Welm BE, Welm AL (2024). TOWARDS Study: Patient-Derived Xenograft Engraftment Predicts Poor Survival in Patients With Newly Diagnosed Triple-Negative Breast Cancer. JCO Precis Oncol, 8, e2300724. ()
    3. Koric A, Chang CE, Lee YA, Wei M, Lee C, Tao R, Wang J, Tay D, Hashibe M (2024). Incident Diabetes among Older Asian, Native Hawaiian and Pacific Islander Women with Breast Cancer. JNCI Cancer Spectr, 8(4). ()
    4. NCCN breast oncology panel (2024). NCCN clinical practice guidelines in oncology, Breast Cancer. Version 1.2024. J Natl Compr Canc Netw.
    5. Hashibe M, Wei M, Lee CJ, Tao R, Koric A, Wang J, Daud A, Tay D, Shen J, Lee YA, Chang CE (2023). Incident Cardiovascular Disease Risk among Older Asian, Native Hawaiian and Pacific Islander Breast Cancer Survivors. Cancer Epidemiol Biomarkers Prev, 33(1), 126-135. ()
    6. Covington MF, Hoffman JM, Morton KA, Buckway B, Boucher KM, Rosenthal RE, Porretta JM, Brownson KE, Matsen CB, Vaklavas C, Ward JH, Wei M, Buys SS, Chittoria N, Yakish ED, Archibald ZG, Burrell LD, Butterfield RI, Yap JT (2023). Prospective Pilot Study of (18)F-Fluoroestradiol PET/CT in Patients With Invasive Lobular Carcinomas. AJR Am J Roentgenol, 221(2), 228-239. ()
    7. Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, Allison KH, Anderson B, Burstein HJ, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Hurvitz SA, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch AM, Lyons J, Mortimer J, Patel SA, Pierce LJ, Rosenberger LH, Rugo HS, Schneider B, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Wei M, Wisinski KB, Young JS, Yeung K, Dwyer MA, Kumar R (2023). NCCN Guidelinesยฎ Insights: Breast Cancer, Version 4.2023. J Natl Compr Canc Netw, 21(6), 594-608. ()
    8. Kalra M, Henry E, McCann K, Karuturi MS, Bustamante Alvarez JG, Parkes A, Wesolowski R, Wei M, Mougalian SS, Durm G, Qin A, Schonewolf C, Trivedi M, Armaghani AJ, Wilson FH, Iams WT, Turk AA, Vikas P, Cecchini M, Lubner S, Pathak P, Spencer K, Koshkin VS, Labriola MK, Marshall CH, Beckermann KE, theMednetorg NCI-CCC Tumor Board Program Collaborative Group, Sharifi MN, Bejjani AC, Hotchandani V, Housri S, Housri N (2022). Making National Cancer Institute-Designated Comprehensive Cancer Center Knowledge Accessible to Community Oncologists via an Online Tumor Board: Longitudinal Observational Study. JMIR Cancer, 8(2), e33859. ()
    9. Sharma A, Johnson KB, Bie B, Rhoades EE, Sen A, Kida Y, Hockings J, Gatta A, Davenport J, Arcangelini C, Ritzu J, DeVecchio J, Hughen R, Wei M, Thomas Budd G, Lynn Henry N, Eng C, Foss J, Rotroff DM (2022). A Multimodal Approach to Discover Biomarkers for Taxane-Induced Peripheral Neuropathy (TIPN): A Study Protocol. Technol Cancer Res Treat, 21, 15330338221127169. ()
    10. Wei M, Wang X, Zimmerman DN, Burt LM, Haaland B, Henry NL (2021). Endocrine therapy and radiotherapy use among older women with hormone receptor-positive, clinically node-negative breast cancer. Breast Cancer Res Treat, 187(1), 287-294. ()
    11. Bernard PS, Wooderchak-Donahue W, Wei M, Bray SM, Wood KC, Parikh B, McMillin GA (2021). Potential Utility of Pre-Emptive Germline Pharmacogenetics in Breast Cancer. Cancers (Basel), 13(6). ()
    12. Gilreath JA, Wei M, Paul S, Parker CJ, Stenehjem DD, Rodgers GM (2018). Dynamic dosing of romiplostim in patients with immune thrombocytopenia purpura: Two case reports. J Oncol Pharm Pract, 25(3), 719-723. ()
    13. Raspanti GA, Hashibe M, Siwakoti B, Wei M, Thakur BK, Pun CB, Al-Temimi M, Lee YC, Sapkota A (2016). Household air pollution and lung cancer risk among never-smokers in Nepal. Environ Res, 147, 141-5. ()
    14. Raspanti GA, Hashibe M, Siwakoti B, Wei M, Thakur BK, Pun CB, Milrod C, Adhikari S, Lee YC, Sapkota A (2015). Ethnic Variation in Consumption of Traditional Tobacco Products and Lung Cancer Risk in Nepal. Asian Pac J Cancer Prev, 16(14), 5721-6. ()

    Review

    1. Johnson KB, Sharma A, Henry NL, Wei M, Bie B, Hershberger CE, Rhoades EE, Sen A, Johnson RE, Steenblik J, Hockings J, Budd GT, Eng C, Foss J, Rotroff DM (2023). Genetic variations that influence paclitaxel pharmacokinetics and intracellular effects that may contribute to chemotherapy-induced neuropathy: A narrative review. [Review]. Front Pain Res (Lausanne), 4, 1139883. ()

    Case Report

    1. Wei M, Maurer KA, Henry NL (2019). Ovarian remnant syndrome in an aromatase inhibitor-treated patient with BRCA2 mutation following bilateral oophorectomy. Breast J, 25(6), 1254-1256. ()

  • Clinical Trials